65935-10-6

Upstream product

• 501-53-1 benzyl chloroformate 
• 78-96-6 3-amino-2-propanol 
• 156-87-6 propan-1-ol-3-amine 

Downstream Products

• 678166-62-6 2-(benzyloxycarbonyl)amino-1-methylethyl thioacetate 
• 111491-97-5 (2-oxopropyl)carbamic acid benzyl ester 
• 869563-78-0 (2,2-dimethoxypropyl)carbamic acid benzyl ester 
• 130793-70-3 (2R)-N-benzyloxycarbonyl-2-hydroxypropylamine 
• 463967-83-1 benzyl N-[(2S)-2-hydroxypropyl]carbamate 

Relevant academic research and scientific papers

CHEMICAL COMPOUNDS

A compound of formula (I), wherein Ar1, R21, R23, R24, R25, R26, R27, A, X, Y and W are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Diarylpyrazole compound, composition containing the same and application thereof

The invention provides a diarylpyrazole compound, a composition containing the same and application thereof. The diarylpyrazole compound is the compound shown as formula (I) or its tautomer, stereisomer, prodrug, crystal form, pharmaceutically acceptable

NOVEL HIGH AFFINITY QUINOLINE-BASED KINASE LIGANDS

Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.

Novel high affinity quinoline-based kinase ligands

Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.

γ-Carboline derivatives with anti-bovine viral diarrhea virus (BVDV) activity

Based on anti-viral screening of our heteroaromatics derived from thalidomide, the γ-carboline skeleton has been identified as a superior scaffold structure for compounds with potent anti-bovine viral diarrhea virus (BVDV) activity. Structural development studies led to a potent anti-viral agent, SK5M (5-methyl-γ-carboline), with the EC50 of 0.26 μM.

Molecular transporter between polymer platforms: Highly efficient chemoenzymatic glycopeptide synthesis by the combined use of solid-phase and water-soluble polymer supports

(Figure Presented) The molecule standing at platform one ...: Rapid glycopeptide synthesis is achieved with a heterobifunctional "molecular transporter" (see scheme), which interfaces two types of polymer platforms for combined chemical and enzymatic synt

A General Route to the Synthesis of N-Protected 1-Substituted and 1,2-Disubstituted Taurines

N-Benzyloxycarbonyl protected α-substituted and αβ- disubstituted taurines were synthesized from olefins and epoxides via N-benzyloxycarbonylamino alcohol thioacetates as key intermediates. They are important sulfur analogues of naturally occurring amino acids and building blocks for the synthesis of α-substituted and α,β- disubstituted β-sulfonopeptides.

Triasulfurone compounds

The present invention relates to monoclonal antibodies that are distinguished by a high degree of selectivity and affinity towards triasulfurone and that are therefore outstandingly suitable for use in an immunoassay for the rapid and effective detection